Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome

Ruifeng Tian,Jinjie Yang,Xiaoming Wang,Shuaiyang Liu,Ruixiang Dong,Zhenya Wang,Zifeng Yang,Yingping Zhang,Zhiwei Cai,Hailong Yang,Yufeng Hu,Zhi-Gang She,Hongliang Li,Junjie Zhou,Xiao-Jing Zhang
DOI: https://doi.org/10.1186/s13020-023-00729-5
IF: 4.546
2023-03-19
Chinese Medicine
Abstract:Non-alcoholic fatty liver (NAFLD) and its related metabolic syndrome have become major threats to human health, but there is still a need for effective and safe drugs to treat these conditions. Here we aimed to identify potential drug candidates for NAFLD and the underlying molecular mechanisms.
pharmacology & pharmacy,integrative & complementary medicine
What problem does this paper attempt to address?